Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.
-
Arang N, Lubrano S, Ceribelli M, Rigiracciolo DC, Saddawi-Konefka R, Faraji F, Ramirez SI, Kim D, Tosto FA, Stevenson E, Zhou Y, Wang Z, Bogomolovas J, Molinolo AA, Swaney DL, Krogan NJ, Yang J, Coma S, Pachter JA, Aplin AE, Alessi DR, Thomas CJ, Gutkind JS. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. Cell Rep Med. 2023 11 21; 4(11):101244.
-
Guo T, Zou X, Sundar S, Jia X, Dhong C. In situ measurement of viscoelastic properties of cellular monolayers via graphene strain sensing of elastohydrodynamic phenomena. Lab Chip. 2023 09 13; 23(18):4067-4078.
-
Duan X, Perveen R, Dandamudi A, Adili R, Johnson J, Funk K, Berryman M, Davis AK, Holinstat M, Zheng Y, Akbar H. Pharmacologic targeting of Cdc42 GTPase by a small molecule Cdc42 activity-specific inhibitor prevents platelet activation and thrombosis. Sci Rep. 2021 06 23; 11(1):13170.
-
Liu T, Liu J, Lu HR, Li H, Gallacher DJ, Chaudhary K, Wang Y, Yan GX. Utility of Normalized TdP Score System in Drug Proarrhythmic Potential Assessment: A Blinded in vitro Study of CiPA Drugs. Clin Pharmacol Ther. 2021 06; 109(6):1606-1617.
-
Di Diego JM, Patocskai B, Barajas-Martinez H, Borb?th V, Ackerman MJ, Burashnikov A, Clatot J, Li GR, Robinson VM, Hu D, Antzelevitch C. Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes. PLoS One. 2020; 15(11):e0242747.
-
Gill J, Zhang W, Zhang Z, Roth M, Harrison DJ, Rowshan S, Erickson S, Gatto G, Kurmasheva R, Houghton P, Teicher B, Smith MA, Kolb EA, Gorlick R. Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. Pediatr Blood Cancer. 2020 10; 67(10):e28606.
-
Du Pont V, Wirblich C, Yoon JJ, Cox RM, Schnell MJ, Plemper RK. Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor. J Virol. 2020 06 16; 94(13).
-
Frerichs KA, Broekmans MEC, Marin Soto JA, van Kessel B, Heymans MW, Holthof LC, Verkleij CPM, Boominathan R, Vaidya B, Sendecki J, Axel A, Gaudet F, Pillarisetti K, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Preclinical Activity of JNJ-7957, a Novel BCMA?CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clin Cancer Res. 2020 05 01; 26(9):2203-2215.
-
Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. Clin Cancer Res. 2019 04 01; 25(7):2278-2289.
-
Woody MS, Greenberg MJ, Barua B, Winkelmann DA, Goldman YE, Ostap EM. Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke. Nat Commun. 2018 09 21; 9(1):3838.